IL-17A Promotes Epithelial ADAM9 Expression in Cigarette Smoke-Related COPD
Danyang Li,Tong Wang,Qianli Ma,Lu Zhou,Yanqing Le,Yafei Rao,Liang Jin,Yuqiang Pei,Yaning Cheng,Chen Huang,Xiaoyan Gai,Yongchang Sun
DOI: https://doi.org/10.2147/COPD.S375006
2022-10-14
International Journal of COPD
Abstract:Danyang Li, 1 Tong Wang, 2 Qianli Ma, 3 Lu Zhou, 1 Yanqing Le, 1 Yafei Rao, 1 Liang Jin, 1 Yuqiang Pei, 1 Yaning Cheng, 4 Chen Huang, 5 Xiaoyan Gai, 1 Yongchang Sun 1 1 Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 2 Department of Thoracic Surgery, Peking University Third Hospital, Beijing, 100191, People's Republic of China; 3 Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, 100029, People's Republic of China; 4 School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, People's Republic of China; 5 Center of Basic Medical Research, Peking University Third Hospital, Beijing, 100191, People's Republic of China Correspondence: Xiaoyan Gai; Yongchang Sun, Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, No. 49 North Garden Road, Haidian District, Beijing, 100191, People's Republic of China, Email ; Background: It has been reported that a disintegrin and metalloproteinase 9 (ADAM9) is involved in the pathogenesis of cigarette smoke (CS)-associated chronic obstructive pulmonary disease (COPD). But how CS exposure leads to upregulation of ADAM9 remains unknown. Methods: Patients who underwent lobectomy for a solitary pulmonary nodule were enrolled and divided into three groups: non-smokers with normal lung function, smokers without COPD and smoker patients with COPD. Immunoreactivity of interleukin (IL)-17A and ADAM9 in small airways and alveolar walls was measured by immunohistochemistry. Wild-type and Il17a −/− C57BL/6 mice were exposed to CS for six months, and ADAM9 expression in the airway epithelia was measured by immunoreactivity. In addition, the protein and mRNA expression levels of IL-17A and ADAM9 were assessed in CS extract (CSE) and/or IL-17A-treated human bronchial epithelial (HBE) cells. Results: The immunoreactivity of ADAM9 was increased in the airway epithelia and alveolar walls of patients with COPD compared to that of the controls. The expression of IL-17A was also upregulated in airway epithelial cells of patients with COPD and correlated positively with the level of ADAM9. The results from the animal model showed that Il17a −/− mice were protected from emphysema induced by CS exposure, together with a reduced level of ADAM9 expression in the airway epithelia, suggesting a possible link between ADAM9 and IL-17A. Consistently, our in vitro cell model showed that CSE stimulated the expression of ADAM9 and IL-17A in HBE cells in a dose- and time-dependent manner. Recombinant IL-17A induced ADAM9 upregulation in HBE cells and had a synergistic effect with CSE, whereas blocking IL-17A inhibited CSE-induced ADAM9 expression. Further analysis revealed that IL-17A induced c-Jun N-terminal kinase (JNK) phosphorylation, thereby increasing ADAM9 expression. Conclusion: Our results revealed a novel role of IL-17A in CS-related COPD, where IL-17A contributes to ADAM9 expression by activating JNK signaling. Keywords: chronic obstructive pulmonary disease, a disintegrin and metalloproteinase 9, interleukin-17A, airway epithelium Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory disease characterized by a progressive decline of lung function resulting from alveolar destruction and airway remodeling. It has become a leading cause of morbidity and mortality worldwide and results in a substantial economic and social burden. 1 Cigarette smoking is a major risk factor for COPD. 1 Inhalation of cigarette smoke (CS) activates the innate and adaptive immune systems, leading to the release of a range of inflammatory mediators, including cytokines, chemokines, and proteases. 2 Uncontrolled protease secretion contributes to the degradation of the extracellular matrix (ECM) components, and hence airspace enlargement (emphysema), a hallmark of COPD. 3 A variety of proteases, such as serine proteinases, cysteine proteinases, and matrix metalloproteases (MMPs), have been reported to participate in the development of emphysema, 3 whereas a disintegrin and metalloproteinases (ADAMs), such as ADAM8, 4 ADAM9, 5,6 ADAM15, 7 and ADAM33, 8 as a less studied subgroup of metalloproteinases, were found to be involved in COPD pathogenesis in recent years. ADAMs are type I transmembrane proteins containing six important domains, among which the metalloproteinase and disintegrin domains endow them with proteolytic and adhesive functions, respectively.<sup -Abstract Truncated-
respiratory system